Boston Scientific reported second quarter 2026 net sales of $5.442 billion, a 7.5% increase on a reported basis and 7.0% on an operational basis compared to the prior year period. GAAP net income attributable to common stockholders was $907 million, or $0.61 per share, while adjusted EPS reached $0.86, beating the guidance range of $0.82 to $0.84. The company completed a previously announced $2 billion accelerated share repurchase program, acquiring approximately 40 million shares. Additionally, Boston Scientific invested $1.5 billion in MiRus LLC for an approximate 34% equity stake and exclusive option to acquire the MiRus TAVR business. Management raised full-year 2026 adjusted EPS guidance to $3.28–$3.32 and third-quarter net sales growth guidance to 3–5%. Boston Scientific is a global medical technology company that develops, manufactures, and sells minimally invasive interventional medical devices.
